Epidemiological Characteristics of Candida auris Candiduria

Abstract

Background: Candida auris infections have become a significant global clinical problem due to their increasing frequency, especially in intensive care patients, and high rates of antifungal resistance. This study aimed to evaluate the epidemiological characteristics and antifungal susceptibility profiles of candiduria caused by C. auris.

Materials and Methods: Demographic data of 115 patients whose urine cultures grew C. auris were analyzed retrospectively at the Microbiology Laboratory of Adana City Training and Research Hospital between February and September 2025. Species identification of isolates was performed using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) with a Microflex LT MALDI-TOF MS system (Bruker Daltonics, Bremen, Germany). Antifungal susceptibility testing was performed using the Sensititre YeastOne YO10 AST (Thermo Scientific™, Waltham, MA, USA) commercial kit, and results were interpreted according to the tentative breakpoints recommended by the Centers for Disease Control and Prevention.

Results: The median age of patients was 65, and 62.6% of the cases were male patients. It was determined that clinical samples were sent more frequently from intensive care unit (76.5%) [internal medicine (18.3%), anesthesiology and resuscitation (17.4%), brain surgery (10.4%) and neurology (9.6%)]. The highest resistance rates were found for fluconazole (n=130, 99.2%) and amphotericin B (n=88, 67.2%), respectively. The resistance rates for caspofungin, micafungin, and anidulafungin were 9.2%, 5.3%, and 3.8%, respectively. The proportion of pan-resistant isolates was found to be 6.9% (n=9/131). Resistance development was detected in two cases under echinocandin treatment.

 Conclusions: Candida auris candiduria is associated with advanced age, intensive care unit admission, and the presence of a urinary catheter. Multiple antifungal resistance creates significant therapeutic challenges. Therefore, routine antifungal susceptibility testing for each isolate, strengthening epidemiological surveillance, and implementing control strategies to prevent resistance development are critical for the effective management of C. auris infections.

 

Keywords

• Candida auris
• candiduria
• epidemiology
• antifungal resistance

Ethical Statement

Bu çalışma, Adana Şehir Eğitim ve Araştırma Hastanesi Bilimsel Araştırmalar Etik Kurulu tarafından onaylanmıştır (karar no:780, tarih: 25.09.2025) onay alındı.

Candida auris Kandidürilerinin Epidemiyolojik Özellikleri

Abstract

Amaç: Candida auris enfeksiyonları, özellikle yoğun bakım hastalarında artan sıklığı ve yüksek antifungal direnç oranları nedeniyle küresel ölçekte önemli bir klinik sorun haline gelmiştir. Bu çalışma, C. auris kaynaklı kandidürilerin epidemiyolojik özellikleri ile antifungal duyarlılık profillerini değerlendirmeyi amaçlamaktadır.

Materyal ve metod: Şubat-Eylül 2025 tarihleri arasında Adana Şehir Eğitim ve Araştırma Hastanesi Mikrobiyoloji Laboratuvarı’nda idrar kültürlerinde C. auris üreyen 115 hastanın demografik verileri retrospektif olarak incelendi. İzolatların tür tanımlaması, matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) yöntemi ile Microflex LT MALDI-TOF MS (Bruker Daltonics, Bremen, Almanya) sistemi kullanılarak yapıldı. Antifungal duyarlılık testleri Sensititre YeastOne YO10 AST (Thermo Scientific™, Waltham, MA, ABD) ticari kiti kullanılarak yapıldı ve sonuçlar Centers for Disease Control and Prevention tarafından önerilen geçici sınır değerlerine göre yorumlandı.

Bulgular: Hastaların medyan yaşı 65 olup olguların %62,6’sı erkek hastalardan oluşmakta idi. Klinik örneklerin daha sıklıkla yoğun bakım ünitelerinden (%76,5) [dahiliye (%18,3), anesteziyoloji ve reanimasyon (%17,4), beyin cerrahisi (%10,4) ve nöroloji (%9,6)] gönderildiği belirlendi. En yüksek direnç oranları sırası ile flukonazol (n=130, %99,2) ve amfoterisin B (n=88, %67,2) için bulundu.  Kaspofungin, mikafungin ve anidulafungin direnç oranları, sırası ile, %9,2, %5,3 ve %3,8 idi. Pan-rezistan izolatların oranı %6,9 (n=9/131) tespit edildi. Ekinokandin tedavisi altında iki olguda direnç gelişimi tespit edildi.

Sonuç: Candida auris kandidürileri, ileri yaş, yoğun bakım yatışı ve üriner kateter varlığı ile ilişkilidir. Çoklu antifungal ilaç direnci, tedavi yaklaşımlarında önemli güçlükler yaratmaktadır. Bu nedenle, her izolat için antifungal duyarlılık testlerinin rutin uygulanması, epidemiyolojik sürveyansın güçlendirilmesi ve direnç gelişimini önleyici kontrol stratejilerinin benimsenmesi C. auris enfeksiyonlarının etkin yönetimi açısından kritik öneme sahiptir.

 

Keywords

• Candida auris
• kandidüri
• epidemiyoloji
• antifungal direnç

Ethical Statement

Bu çalışma, Adana Şehir Eğitim ve Araştırma Hastanesi Bilimsel Araştırmalar Etik Kurulu tarafından onaylanmıştır (karar no:780, tarih: 25.09.2025) onay alındı.

References

1. 1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41-4.
2. 2. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis. 2017;64(2):134-40.
3. 3. Eix EF, Nett JE. Candida auris: Epidemiology and Antifungal Strategy. Annu Rev Med. 2025;76(1):57-67.
4. 4. WHO fungal priority pathogens list to guide research, development and public health action. [Internet]. 1st ed. CC BY-NC-SA 3.0 IGO: World Health Organization; 2022. 1 p. Available from: CIP data are available at http://apps.who.int/iris.
5. 5. Alfouzan WA, Dhar R. Candiduria: Evidence-based approach to management, are we there yet? J Mycol Médicale. 2017;27(3):293-302.
6. 6. Castellano-Sánchez L, Rosales-Castillo A, Marcos-Rodríguez R, Olvera-Porcel MC, Navarro-Marí JM, Gutiérrez-Fernández J. Microbiological Relevance of Candida in Urine Cultures. J Fungi. 2025;11(7):483.
7. 7. Korkmaz D, Demi̇Rtürk N, Keşli̇ R, Konya P. Hospitalize kandidürili hastalarda risk faktörlerinin araştırılması. Acta Medica Alanya. 2019;3(1):72-7.
8. 8. Erkol Yilmaz Y, Havan M, Eyduran E, Penezoğlu N, Öcal D, Teber S, et al. Successful Treatment of Bladder Fungus Ball Due to Candida auris With Systemic/Local Amphotericin B and Surgical Excision. Cozzi DA, editor. Case Rep Pediatr. 2025;(1):9741756.

9. 9. La Bella AA, Santiago-Tirado FH, Flores-Mireles AL. Candida auris is emerging as a prevalent urinary pathogen. PLOS Pathog. 2025;21(5):e1013138.
10. 10. Fazeli A, Kordbacheh P, Nazari A, Daie Ghazvini R, Mirhendi H, Safara M, et al. Candiduria in Hospitalized Patients and Identification of Isolat-ed Candida Species by Morphological and Molecular Methods in Ilam, Iran. Iran J Public Health. 2019;48(1):156-61.
11. 11. Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method. J Clin Microbiol. 2015;53(6):1823-30.
12. 12. Li J, Wang Z, Zheng R, Wang Y, Guo X, Li X, et al. Identification, antifungal resistance, and genomic characterization of a single Candida auris isolate from urinary tract infection. Front Cell Infect Microbiol. 2025;15:1641542.
13. 13. Griffith N, Danziger L. Candida auris Urinary Tract Infections and Possible Treatment. Antibiotics. 2020;9(12):898.
14. 14. Pemán J, Ruiz-Gaitán A. Candidemia from urinary tract source: the challenge of candiduria. Hosp Pract. 2018;46(5):243-5.
15. 15. Biagi MJ, Wiederhold NP, Gibas C, Wickes BL, Lozano V, Bleasdale SC, et al. Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candida auris Candidemia Secondary to Chronic Candiduria. Open Forum Infect Dis. 2019;6(7):ofz262.
16. 16. Worku M, Girma F. Candida auris: From Multidrug Resistance to PanResistant Strains. Infect Drug Resist. 2020;13:1287-94.
17. 17. Kim JS, Cha H, Bahn YS. Comprehensive Overview of Candida auris : An Emerging Multidrug-Resistant Fungal Pathogen. J Microbiol Biotechnol. 2024;34(7):1365-75.
18. 18. Jacobs SE, Jacobs JL, Dennis EK, Taimur S, Rana M, Patel D, et al. Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents. Antimicrob Agents Chemother. 2022;66(7):e00053-22.
19. 19. Lanna M, Lovatto J, Almeida JN de, Medeiros EA, Colombo AL, García-Effron G. Epidemiological and Microbiological aspects of Candidozyma auris (Candida auris) in Latin America: A literature review. J Med Mycol. 2025;35(2):101546.
20. 20. Jones CR, Neill C, Borman AM, Budd EL, Cummins M, Fry C, et al. The laboratory investigation, management, and infection prevention and control of Candida auris: a narrative review to inform the 2024 national guidance update in England: This article is part of the Candida collection. J Med Microbiol. 2024;73(5):001820.
21. 21. Sanyaolu A, Okorie C, Marinkovic A, Abbasi AF, Prakash S, Mangat J, et al. Candida auris : An Overview of the Emerging Drug-Resistant Fungal Infection. Infect Chemother. 2022;54(2):236.
22. 22. O’Brien B, Liang J, Chaturvedi S, Jacobs JL, Chaturvedi V. Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations. Lancet Microbe. 2020;1(5):e193-4.
23. 23. Zhu HH, Liu MM, Boekhout T, Wang QM. Improvement of a MALDI-TOF database for the reliable identification of Candidozyma auris (formally Candida auris ) and related species. Martin RM, editor. Microbiol Spectr. 2025;13(1):e01444-24.
24. 24. CDC. Candida auris [Internet]. U.S. Department of Health and Human Services: CDC. Atlanta, GA; 2024. Available from: https://www.cdc.gov/candida-auris/hcp/laboratories/antifungal-susceptibility-testing.html
25. 25. Suphavilai C, Ko KKK, Lim KM, Tan MG, Boonsimma P, Chu JJK, et al. Detection and characterisation of a sixth Candida auris clade in Singapore: a genomic and phenotypic study. Lancet Microbe. 2024;5(9):100878.
26. 26. Jain M, Dogra V, Mishra B, Thakur A, Loomba P, Bhargava A. Candiduria in catheterized intensive care unit patients : Emerging microbiological trends. Indian J Pathol Microbiol. 2011;54(3):552.
27. 27. Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, et al. Prospective Multicenter Surveillance Study of Funguria in Hospitalized Patients. Clin Infect Dis. 2000;30(1):14-8.
28. 28. Álvarez-Lerma F, Nolla-Salas J, León C, Palomar M, Jordá R, Carrasco N, et al. Candiduria in critically ill patients admitted to intensive care medical units. Intensive Care Med. 2003;29(7):1069-76.
29. 29. Dias V. Candida Species in the Urinary Tract: Is it a Fungal Infection or Not? Future Microbiol. 2020;15(2):81-3.
30. 30. Chen J, Tian S, Han X, Chu Y, Wang Q, Zhou B, et al. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris. BMC Infect Dis. 2020;20(1):827.
31. 31. De Gaetano S, Midiri A, Mancuso G, Avola MG, Biondo C. Candida auris Outbreaks: Current Status and Future Perspectives. Microorganisms. 2024;12(5):927.
32. 32. Lionakis MS, Chowdhary A. Candida auris Infections. Hardin CC, editor. N Engl J Med. 2024;391(20):1924-35.
33. 33. Siopi M, Peroukidou I, Beredaki MI, Spruijtenburg B, De Groot T, Meis JF, et al. Overestimation of Amphotericin B Resistance in Candida auris with Sensititre YeastOne Antifungal Susceptibility Testing: a Need for Adjustment for Correct Interpretation. Alanio A, editor. Microbiol Spectr. 2023;11(3):e04431-22.
34. 34. Fenton A, John GK. Candida auris Resistance Mechanisms to Amphotericin B Alternative Treatments Development. Curr Clin Microbiol Rep. 2024;11(3):166-76.
35. 35. Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6(1):69.
36. 36. Kim HY, Nguyen TA, Kidd S, Chambers J, Alastruey-Izquierdo A, Shin JH, et al. Candida auris —a systematic review to inform the world health organization fungal priority pathogens list. Med Mycol. 2024;62(6):myae042.
37. 37. Lockhart SR. Candida auris and multidrug resistance: Defining the new normal. Fungal Genet Biol. 2019;131:103243.
38. 38. Silva KJG da, Lucini F, Santos RAC dos, Santos DA, Meis JF, Melhem M de SC, et al. How does antifungal resistance vary in Candida (Candidozyma) auris and its clades? Quantitative and qualitative analyses and their clinical implications. Clin Microbiol Infect. 2025;31(7):1146-56.
39. 39. Spruijtenburg B, Ahmad S, Asadzadeh M, Alfouzan W, Al‐Obaid I, Mokaddas E, et al. Whole genome sequencing analysis demonstrates therapy‐induced echinocandin resistance in Candida auris isolates. Mycoses. 2023;66(12):1079-86.
40. 40. Rhodes J, Jacobs J, Dennis EK, Manjari SR, Banavali NK, Marlow R, et al. What makes Candida auris pan-drug resistant? Integrative insights from genomic, transcriptomic, and phenomic analysis of clinical strains resistant to all four major classes of antifungal drugs. Groll AH, editor. Antimicrob Agents Chemother. 2024;68(10):e00911-24.